Here’s what you should know:
1. Year to date, Motus GI reported $16.7 million in net losses, totaling a $1.13 loss per share.
2. Despite the losses, Motus has $11.6 million in cash and short-term investments.
3. Motus is readying for the commercial launch of its colonoscopy preparing Pure-Vu System in 2019.
4. Motus GI CEO Tim Moran said, “We have made significant progress in recent months to ensure the company is positioned for a successful commercial launch of the Pure-Vu System in 2019.”
5. Motus appointed Mr. Moran as CEO during the third quarter. Former CEO Mark Pomeranz will continue serving as the company’s president and COO.
More articles on gastroenterology:
FDA approves opioid 10x stronger than fentanyl as crisis continues — 5 insights
Twin Cities Pain Clinic radiologic technologist discusses job perks, misconceptions & more — 3 quotes
Quarterly reports on Tenet, Surgery Partners & more — 8 ASC company key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
